Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 159 publications
Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.
Journal: The New England journal of medicine
Published: September 02, 2026
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).
Journal: American journal of hematology
Published: June 25, 2026
Chewing the fat: the role of total cholesterol in MPN management.
Journal: Blood advances
Published: May 26, 2026
A novel hyperactive BCR::ABL1 e6a3 variant confers resistance to combined asciminib plus ponatinib therapy.
Journal: medRxiv : the preprint server for health sciences
Published: May 04, 2026
Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunity.
Journal: Science (New York, N.Y.)
Published: April 09, 2026
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.
Journal: Blood cancer journal
Published: March 13, 2026
Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia.
Journal: British journal of haematology
Published: December 08, 2025
Hematologic responses achieved with luspatercept in higher-risk myelodysplastic syndromes.
Journal: Blood advances
Published: December 01, 2025
Clinical strategies for leukemia management: Recommendations from the Bridging the Gaps in Hematology Oncology Consensus Conference 2025.
Journal: Leukemia research
Published: September 16, 2025
Last Updated: 09/26/2026